Investing in the Future of Repair.
We are pioneering a new class of therapeutics to program stromal behavior, creating a pipeline of first-in-class candidates with the potential for durable, regenerative outcomes.
- Novel Biology Platform
- De-risked Regulatory Pathway
- World-Class Founding Team
Our Strategic Pillars
Investment Thesis
Novel Biology
Targeting the stromal microenvironment, an untapped nexus of control in complex diseases.
Differentiated Pipeline
First-in-class candidates addressing multiple high-value indications with significant unmet needs.
Robust IP Position
Strong intellectual property with composition of matter patents filed for our lead chemical series.
De-risked Pathway
Leveraging the accelerated 505(b)(2) pathway to reduce time and cost to market.
Milestones
Q1 2025
Core platform technology validation achieved, unlocking a novel class of druggable stromal targets.
Q2 2025
Advanced in-vivo efficacy studies for AT-002; early readouts successfully guide dose selection.
Q3 2025
Preclinical evidence package for our AT-002 program submitted to a high-impact translational journal.
Founding Team
Begin the Conversation
We are actively seeking partners and investors who share our vision. For access to our data room and to discuss collaboration opportunities, please contact our investor relations team.
Contact IR